ABEONA THERAPEUTICS INC. (ABEO)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Abeona Therapeutics Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 9, 2026 | 3.62 | 3.62 | 3.04 | 3.17 | 829,396 |
| Nov 6, 2026 | 4.02 | 4.26 | 3.95 | 4.17 | 1,049,744 |
| Nov 5, 2026 | 4.19 | 4.25 | 3.91 | 3.91 | 1,546,634 |
| Nov 4, 2026 | 4.36 | 4.42 | 4.19 | 4.22 | 881,735 |
| Nov 3, 2026 | 4.27 | 4.40 | 4.20 | 4.25 | 1,123,325 |
| Nov 2, 2026 | 4.43 | 4.46 | 4.16 | 4.25 | 1,011,828 |
| Oct 30, 2026 | 4.50 | 4.53 | 4.30 | 4.35 | 783,431 |
| Oct 29, 2026 | 4.54 | 4.73 | 4.47 | 4.56 | 874,335 |
| Oct 28, 2026 | 4.46 | 4.58 | 4.44 | 4.55 | 618,146 |
| Oct 27, 2026 | 4.33 | 4.50 | 4.30 | 4.45 | 663,678 |
| Oct 26, 2026 | 4.39 | 4.41 | 4.30 | 4.31 | 426,579 |
| Oct 23, 2026 | 4.42 | 4.43 | 4.29 | 4.40 | 797,294 |
| Oct 22, 2026 | 4.46 | 4.61 | 4.38 | 4.47 | 717,809 |
| Oct 21, 2026 | 4.62 | 4.67 | 4.50 | 4.51 | 643,558 |
| Oct 20, 2026 | 4.43 | 4.64 | 4.40 | 4.60 | 1,393,703 |
| Oct 19, 2026 | 4.47 | 4.49 | 4.32 | 4.41 | 986,053 |
| Oct 16, 2026 | 4.66 | 4.66 | 4.39 | 4.43 | 819,512 |
| Oct 15, 2026 | 4.39 | 4.79 | 4.35 | 4.65 | 1,377,238 |
| Oct 14, 2026 | 4.48 | 4.51 | 4.28 | 4.36 | 1,773,942 |
| Oct 13, 2026 | 4.88 | 4.88 | 4.50 | 4.52 | 1,980,151 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Vasanthavada Madhav | Chief Commercial Officer | Sale | 4.9K | $25.3K | Sep 29, 2026 |
 O'Malley Brendan M. | SVP, Chief Legal Officer | Sale | 6.7K | $34.7K | Sep 29, 2026 |
 Vazzano Joseph Walter | Chief Financial Officer | Sale | 9.2K | $47.4K | Sep 29, 2026 |
 Seshadri Vishwas | Chief Executive Officer | Sale | 19.6K | $101.1K | Sep 29, 2026 |
 Alvino Mark | Director | Sale | 15.0K | $88.0K | Sep 1, 2026 |
| Vazzano Joseph Walter | Chief Financial Officer | Sale | 1.5K | $9.7K | Jul 21, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Nantahala Capital Management, LLC · also on 13F· joint filing· may incl. warrants· filed May 2026 | 5.8M | 10.1% | 13G |
Nantahala Capital Management, LLC | 5.1M | 9.0% | 13F |
James Russell Revocable Trust · joint filing· may incl. warrants· filed Oct 2026 | 3.5M | 6.1% | 13D |
BlackRock, Inc. | 3.4M | 5.9% | 13F |
NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP · may incl. warrants· reaffirmed 13F Aug 2026 | 3.3M | 5.8% | 13G |
Cable Car Capital, LP | 3.0M | 5.3% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Jul 2025 | 2.9M | 5.2% | 13G |
AIGH Capital Management LLC | 2.9M | 5.1% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | 3.9% | 13F |
OneDigital Investment Advisors LLC | 1.7M | 2.9% | 13F |
Insiders
- Vasanthavada MadhavChief Commercial Officer
- O'Malley Brendan M.SVP, Chief Legal Officer
- Vazzano Joseph WalterChief Financial Officer
- Seshadri VishwasChief Executive Officer
- Alvino MarkDirector
- Alland LeilaDirector
- Silverstein Christine BerniDirector
- Crombez EricDirector
- Goldan Keith A.Director
- Wuchterl Donald A.Director
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases.
Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa.
The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders.
Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform.
The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
based on 57.18M shares outstanding
US30d Avg
1.01M
60d Avg
1.23M
90d Avg
1.35M